Undisclosed PolyCol program

About Stuart Therapeutics

Stuart Therapeutics is a private, clinical-stage biotech pioneering a novel approach to treating chronic ocular diseases by targeting helical collagen in the extracellular matrix. Its proprietary PolyCol platform technology consists of synthetic peptides designed to bind and repair damaged collagen, a previously 'undruggable' target involved in inflammation and tissue structure. The company's most advanced asset, ST-100 (Vezocolmitide), has reported Phase III results for Dry Eye Disease, and it has secured a key partnership with Glaukos Corporation. With a pipeline focused on major unmet needs in ophthalmology, Stuart aims to develop disease-modifying therapies that go beyond symptom management.

About Stuart Therapeutics

Stuart Therapeutics is a private, clinical-stage biotech pioneering a novel approach to treating chronic ocular diseases by targeting helical collagen in the extracellular matrix. Its proprietary PolyCol platform technology consists of synthetic peptides designed to bind and repair damaged collagen, a previously 'undruggable' target involved in inflammation and tissue structure. The company's most advanced asset, ST-100 (Vezocolmitide), has reported Phase III results for Dry Eye Disease, and it has secured a key partnership with Glaukos Corporation. With a pipeline focused on major unmet needs in ophthalmology, Stuart aims to develop disease-modifying therapies that go beyond symptom management.

Therapeutic Areas

Other Glaucoma Drugs